Form 4: OrbiMed Advisors Sells Shares of Keros Therapeutics

OrbiMed Advisors LLC, along with related entities, sold shares of Keros Therapeutics, Inc. on August 13, 2024.

Summary

• OrbiMed Advisors LLC, OrbiMed Capital GP VII LLC, and OrbiMed Genesis GP LLC jointly filed a Form 4 regarding transactions in Keros Therapeutics, Inc. (KROS) stock.
• On August 13, 2024, they disposed of 220,600 shares of Common Stock at a price of $44.01.
• Additionally, they disposed of 29,400 shares of Common Stock at the same price.
• Following these transactions, OrbiMed Private Investments VII, LP beneficially owns 899,212 shares.
• OrbiMed Genesis Master Fund, L.P. beneficially owns 119,522 shares.
• The reporting persons disclaim beneficial ownership except to the extent of their pecuniary interest.

Sentiment

Score: 5

Explanation: Neutral sentiment as it reports a transaction (share disposal) without expressing any positive or negative outlook.

Negatives

• OrbiMed Advisors LLC and related entities reduced their holdings in Keros Therapeutics through the sale of shares.

Management Comments

• Carl L. Gordon, a member of OrbiMed Advisors, serves on the Issuer's board of directors.
• Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the 'Exchange Act'), except to the extent of its pecuniary interest therein, if any.

Stakeholder Impact

• The sale of shares by a major shareholder like OrbiMed could potentially influence investor sentiment.

Key Dates